Dave Elder (David P Elder Constultancy)

article

Prodrugs: seeking perfection in an imperfect world

28 June 2024 | By Dave Elder (David P Elder Constultancy)

Balancing safety, efficacy and cost in drug development is challenging. Prodrugs offer potential solutions, but also introduce additional complexities, as Dave Elder explains.

article

Accelerating drug development

22 February 2023 | By Dave Elder (David P Elder Constultancy)

Here, Dave Elder explores how a ‘quick-approval, quick-withdrawal from the market’ approach is used to accelerate drug development.

article

The lingering menace of diethylene glycol / ethylene glycol adulteration

13 December 2022 | By Dave Elder (David P Elder Constultancy)

Although it was first identified in the 1930s, diethylene and ethylene glycol contamination remains an issue today, as Dave Elder explains.

article

Patents: a necessary evil?

19 October 2022 | By Dave Elder (David P Elder Constultancy)

Dave Elder explores US patent developments amid growing concerns that current approaches potentially delay generic drugs and biosimilars entering the market.

article

API nitrosamines: method sensitivity issues

25 August 2022 | By Dave Elder (David P Elder Constultancy)

Here, David Elder discusses the risks presented by active pharmaceutical ingredient nitrosamines and explains how European and US guidance differs on their acceptable levels.

article

Paediatric medicines: just a spoonful of sugar?

26 August 2021 | By Dave Elder (David P Elder Constultancy)

Here, Dave Elder discusses the ever increasing importance of child-friendly medications and the specific challenges associated with their development.

article

ICH M13: Bioequivalence guidelines

29 June 2021 | By Dave Elder (David P Elder Constultancy)

Dave Elder outlines how bioequivalence data supports numerous processes at various stages of drug development as well as when establishing generic drug substitution, and reflects on its differing interpretations across the globe.

article

Antibody-drug conjugates: challenges, solutions and future potential

20 April 2021 | By Dave Elder (David P Elder Constultancy), Stacey Treichler (Catalent)

The ability to precisely direct powerful therapeutics not only makes treatments more effective, but also prevents debilitating side effects. Here, Dave Elder and Stacey Treichler highlight the great potential of antibody-drug conjugates (ADCs) for improved treatment of oncology indications and beyond.

article

Sourcing of active pharmaceutical ingredients

17 February 2021 | By Dave Elder (David P Elder Constultancy)

Considerations when sourcing active pharmaceutical ingredients (APIs) can often be condensed to ones of economy and purity. Here, Dave Elder highlights the importance of defining those attributes that impact final product quality to ensure pharma companies find the best ingredient suppliers.

reference

The role of ELSIE in evolving current thinking on extractables and leachables

29 January 2020 | By Dave Elder (David P Elder Constultancy)

References for 'The role of ELSIE in evolving current thinking on extractables and leachables', in European Pharmaceutical Review issue 1 2020.

article

Monitoring and controlling drug products and manufacturing processes with NIRS

24 February 2017 | By Dave Elder (David P Elder Constultancy)

Near-infrared spectroscopy (NIRS) is a rapid and non-destructive analytical technique that is important in analysing or profiling both solid and liquid dosage forms, as well as biotechnological products...